We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Novartis reported that its Phase 2 study of CTL019, its investigational chimeric antigen receptor T cell therapy, found that 55 of 59 (93%) pediatric patients with relapsed/refractory acute lymphoblastic leukemia experienced complete remissions. Drug Industry Daily misstated the patient population. Read More
Are pharma companies getting what they pay for in terms of R&D spending? According to a new report from the Deloitte Center for Health Solutions, the answer is no. Read More
FDA Approves Otonomy’s Otiprio
Cardiorentis Gets FDA Fast Track for Heart Failure Drug
Russian Regulators Approve Biocad’s Avastin Biosimilar
NICE Gives Prelim Green Light to Novartis, Astellas Drugs, But Janssen Drug Delayed Read More
The FDA has given its blessing to Wellstat Therapeutics’ Vistogard for the emergency treatment of adults and children who receive an overdose of chemotherapy treatment fluorouracil or capecitabine. Read More
The FDA has granted approval to Genentech’s Alecensa for metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer in patients whose disease has worsened after taking Pfizer’s Xalkori, or who could not tolerate the treatment. Read More
Type 2 diabetes drugs have elevated reporting rates for pancreatitis, hypoglycemia and diabetic ketoacidosis, which adds to suspicions of class-wide side effect issues, especially for DPP-4 drugs, a new analysis from Advera Health Analytics said. Read More
Janssen is petitioning the U.S. Supreme Court to overturn a $124 million verdict that it made false claims about antipsychotic drug Risperdal (risperidone) and hid risk information from physicians. Read More
As Merck looks to expand the indications of its lipid-reducing drug Vytorin to include cardiovascular outcomes, the FDA is asking whether trial findings describe the full picture well enough to substantiate benefit. Read More
Horizon Pharma has acquired Lake Forest, Ill.-based Crealta Holdings for $510 million in cash, in a deal that expands Horizon’s orphan drug business, the Irish firm said Friday. Read More